Enzyme replacemen is the main therapy of Hurler disease, it improve all the following EXCEPT

(D). Enzyme replacement using recombinant a-L-iduronidase has been approved for patients with MPS-l. It reduces organomegaly and ameliorates rate of growth, joint mobility, reduces the number of episodes of sleep apnea and urinary GAG excretion. The enzyme does not cross the blood-brain barrier and does not prevent deterioration of cognition and other neurologic functions